We recently compiled a list of the 10 Most Undervalued US Stocks to Buy According to Hedge Funds. In this article, we are ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Pfizer (NYSE:PFE) stock and Arvinas (NASDAQ:ARVN) stock slip in reaction to mixed Phase 3 data for their breast cancer drug ...

Pfizer’s shares (currently trading at $26.70) have posted a disappointing 10.2% loss, well below the S&P 500’s 3.8% gain.

Pfizer (NYSE:PFE) announced positive outcomes from the Phase 3 VERITAC-2 clinical trial, showing vepdegestrant's promise in treating advanced breast cancer, which could be a significant driver of the ...

Shrewd investors know that bear markets open up great opportunities to pick up shares of excellent companies from the ...

The market sentiment in the next few months is likely to be quite positive for Pfizer. Read why I maintain my strong buy ...

The pharmaceutical industry is evolving continuously with the advancements in drug discovery with Artificial Intelligence (AI ...

Pfizer (PFE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The general mood among these heavyweight investors is divided, with 48% leaning bullish and 37% bearish. Among these notable options, 5 are puts, totaling $799,839, and 22 are calls, amounting to ...

Pfizer (PFE) announced that James List has joined the company as Chief Internal Medicine Officer. List will oversee Pfizer’s Internal Medicine ...

In a report released today, Kerry Holford from Berenberg Bank maintained a Hold rating on Pfizer (PFE – Research Report), with a price target ...